Hmgb1 was initially included in this cohort of candidate DEGs, as it has been shown to be a mediator of neuroimmune responses in many divergent clinical conditions including sepsis, atherosclerosis, cancer, and alcohol use disorder, as well as chronic pain at the peripheral and spinal levels [37,46,47,48,49]. Here, HMGB1 is linked to atherosclerosis.